[POSSIBLE DRUG CORRECTION OF LIPID METABOLISM DISTURBANCES ASSOCIATED WITH METABOLIC SYNDROME IN PATIENTS WITH PSORIASIS].

Eksperimental'naia i klinicheskaia farmakologiia2015PMID: 27051926

Plain Language Summary

Psoriasis patients with metabolic syndrome — a condition involving abnormal blood fats, among other factors — were given either standard therapy alone or standard therapy plus intranasal Semax. Only the Semax group showed significant improvement in all measured lipid markers: total cholesterol, triglycerides, and LDL fell while beneficial HDL rose. Adding Semax to conventional treatment may offer a meaningful benefit for managing metabolic complications in this patient population.

Abstract

It was studied the possibility of correcting lipid metabolism in patients with psoriasis and concomitant metabolic syndrome (MS) by using additional treatment with semax. In group 1, 58 patients received conventional therapy, while 60 patients in group 2 received the same with additional 0.1% semax solution intranasally 600 mg/day for 10 days. It was found that the inclusion of semax in complex treatment of patients with psoriasis complicated by metabolic syndrome led to a decrease in the initially elevated serum levels of total cholesterol, triglycerides, LDL cholesterol and to an increase in the initially reduced levels of HDL cholesterol, in contrast to the standard treatment, which did not produce any statistically significant effect on the levels of total cholesterol, triglycerides, LDL cholesterol, and HDL cholesterol in the blood serum.

Authors

Dontsova, E V